Longeveron Announces Phase 2 Clinical Trial in Japan to

New trial is in collaboration with Japan’s National Center for Geriatrics and Gerontology (NCGG) and Juntendo University Hospital...

Related Keywords

Miami ,Florida ,United States ,Koto ,Japan General ,Japan ,Tokyo ,Japanese ,Hidenori Arai ,Brendan Payne ,National Center ,Drug Administration ,Nasdaq ,Longeveron Inc ,Juntendo University Hospital ,Devices Agency ,Japan Pharmaceuticals ,Juntendo Koto Geriatric Medical Center ,Geoff Green ,Chief Executive Officer ,Hypoplastic Left Heart Syndrome ,Japanese Phase ,Medical Devices Agency ,University Hospital ,Koto City ,Juntendo Koto Geriatric Medical ,Aging Frailty ,Metabolic Syndrome ,Acute Respiratory Distress Syndrome ,Nasdaq Lgvn ,Longeveron ,